Moderna shares experienced a 13% surge to $67.50 during the June 26 trading session, positioning the stock as the S&P 500’s top gainer that day and tracking toward its strongest closing level since September 2024. The rally followed the company’s investor day presentation, which outlined an expansive development pipeline extending far beyond its coronavirus vaccine origins.
The centerpiece reveal was mRNA-6007, Moderna’s inaugural in vivo CAR-T initiative. Clinical development is scheduled to commence in 2027, initially targeting B-cell-mediated autoimmune conditions such as systemic lupus erythematosus.
The in vivo CAR-T methodology engineers a patient’s T-cells to combat disease directly within the body—eliminating the need for laboratory processing. This approach offers speed and cost advantages over conventional ex vivo techniques, which require cell extraction, external modification, and reinfusion.
Moderna faces competition in this emerging field. Eli Lilly entered the space earlier this year through its planned acquisition of Orna Therapeutics to obtain its in vivo CAR-T technology. Lilly’s stock also rose 6% on June 26, driven by favorable EU regulatory feedback on Jaypirca, its oral cancer treatment.
Jefferies analyst Andrew Tsai characterized the early-stage oncology initiatives as having the potential to “meaningfully diversifying the mRNA pipeline.” However, he highlighted Phase III melanoma data anticipated in late 2026 as the more significant near-term catalyst for share price movement. Tsai maintains a Hold rating on Moderna, elevating his price target from $45 to $53.
Edward Tenthoff from Piper Sandler expressed greater optimism, increasing his price target from $69 to $77 while maintaining an Overweight rating. He attributed the adjustment to the pipeline advancements showcased during investor day.
On July 1, CNBC’s Jim Cramer characterized Moderna as “finally investable again,” highlighting its oncology pipeline and increasingly defined profitability trajectory. He observed that the stock has rallied nearly 150% in 2026, ranking among the S&P 500’s strongest performers this year.
Nevertheless, Cramer advocated for a measured approach. “I recommend waiting for a pullback before you buy,” he advised on Mad Money.
Moderna’s investor day materials segmented its development portfolio into three strategic “horizons.” The initial tier encompasses late-stage and commercialized assets. According to Jefferies’ Tsai, the company could potentially commercialize over seven products spanning respiratory, oncology, and rare disease categories within a two-year timeframe.
This would represent substantial growth from the current three-vaccine commercial lineup. The company introduced its inaugural commercial product—the Spikevax COVID-19 vaccine—in 2020.
Current oncology initiatives include mid and late-stage clinical trials for melanoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer. A late-stage study evaluating Moderna’s Intismeran in combination with Merck’s Keytruda for secondary melanoma treatment is expected to deliver results later this year.
From a regulatory perspective, an FDA advisory panel recently recommended approval for Moderna’s investigational influenza vaccine prior to an August 5 decision deadline. The European Commission has already granted approval for the company’s combined Covid and flu vaccine.
The post Moderna (MRNA) Stock Surges 13% Following Strategic Investor Day Reveals appeared first on Blockonomi.
